The global blood glucose monitoring devices market size was valued at 11.71 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 8.0% from 2022 to 2030. The key drivers of the market are the rising incidence of diabetes and the increasing geriatric population prone to diabetes. The market growth is further propelled by the increasing awareness regarding diabetes preventive care and new product launches. Diabetes is a serious and growing problem globally, where the inefficiency of the pancreas to produce insulin results in an increase in blood glucose levels. According to the International Diabetes Federation, in 2021, around 537 million people were diagnosed with diabetes, this number is expected to increase to 643 million by 2030 and 783 million by 2045.
Blood glucose monitoring (BGM) devices are helpful for patients with diabetes in four ways. These devices enable patients and clinicians to detect high or low blood glucose levels, allowing for therapy modifications and protecting patients by confirming acute hypoglycemia or hyperglycemia promptly and by offering patients greater self-care. The technology facilitates patient education about diabetes and its management and encourages people to adopt healthier habits. Blood glucose devices are available in a multitude of sizes, prices, testing times, and ease of use.
The COVID-19 pandemic has opened new opportunities for blood glucose monitoring devices and these devices gained more popularity in the diabetic care market. Awareness regarding the benefits of blood glucose monitoring devices increased among the consumers as during the pandemic, there had been an emphasis on the use of virtual clinics and telemedicine for diabetic management. The blood glucose monitoring devices helped patients and healthcare providers improve glycemic control and potentially increase patient self-management, thus changing diabetes care significantly. Further, a surge in the demand for blood glucose monitoring devices due to the quick response by major market players during the Covid-19 pandemic.
The rapidly changing lifestyle such as the consumption of alcohol and smoking is contributing to the rise in the number of diabetes patients, worldwide. Obesity is also one of the major factors contributing to diabetes. Furthermore, the increasing geriatric population is propelling market growth. According to the WHO, by 2050, the world’s aging population will be about 2 billion from 1 billion in 2020.
The hospital segment held the largest revenue share of over 40.0% in 2021 and is anticipated to lead the market over the forecast period due to the improving infrastructure and increasing healthcare expenditure in hospitals. Moreover, the reliable data that BGM devices provide practitioners in a fraction of seconds and the improvement in patients' quality of life have increased their adoption in the outpatient as well as inpatient hospital settings. Hospitals have additional provisions to store and transfer patient information. Furthermore, during the COVID-19 pandemic, the FDA allowed the use of CGM devices in hospitals, and the possibility of another pandemic in the future is expected to enhance the segment growth.
The home care segment is expected to register the fastest growth rate during the forecast period. The home-based glucose monitoring is revolutionized by the self-monitoring of blood glucose and is the most widely used method of short-term glucose monitoring throughout the world. The self-monitoring blood glucose (SMBG) is an approach through which people with or without diabetes can measure their blood sugar levels in their homes. Based on the reading, the patient can check the effects of their treatment such as diet, insulin, exercise, and stress management.
Self-monitoring blood glucose devices accounted for the largest revenue share of over 65.0% in 2021 owing to the ease of use and low cost. SMBG is considered an important element of diabetes management daily. Self-monitoring of blood sugar is an approach wherein people measure their blood sugar levels with the help of a glucose meter. It is sub-segmented into blood glucose meter, testing strips, and lancets. The testing strips segment accounted for the largest revenue share in 2021 owing to the high usage of these strips and affordability. The segment is expected to expand at a lucrative CAGR over the forecast period.
The continuous blood glucose monitoring (CBGM) devices segment is expected to register the highest growth rate during the forecast period. CBGM is an important diabetes care tool for patients with type 1 diabetes, who are particularly vulnerable to severe and potentially life-threatening hypoglycemia. These devices help in analyzing the glucose level pattern as it provides continuous and real-time blood sugar reading every five minutes. It is sub-segmented into sensors, insulin pumps, and transmitter and receiver. CGM works through a tiny sensor that is inserted under the skin. This sensor measures sugar level and the transmitter wirelessly sends the information to a monitor. The transmitter and receiver segment held the largest revenue share in 2021.
North America led the market with a revenue share of over 35.0% in 2021 owing to its well-established healthcare sector. The increasing prevalence of obesity, high cost of treatment, technological advancements, and new product launches are also expected to drive the regional market. Europe is expected to capture a significant revenue share over the forecast period due to an increase in the geriatric population, which is prone to diabetes. Moreover, improvements in the healthcare sector and the implementation of advanced medical products are augmenting the demand for BGMs in the region.
Asia Pacific is projected to be a lucrative region over the forecast period. Improvements in healthcare facilities and reimbursement policies in developing economies are key factors aiding the growth in this region. China spearheaded the APAC region in 2021 owing to its large diabetes population and rapid economic growth. Furthermore, an increase in awareness regarding diabetes preventive care is augmenting the market growth.
Major players are focusing on new product launches, government approvals, acquisitions, advancements in existing products & technologies, and other strategies to expand their business portfolio & strengthen their presence. For instance, In May 2021, Roche collaborated with Eli Lilly and Company, to work towards enhancing the management of insulin pen therapy. With this collaboration, Roche follows its ambition to create an open ecosystem including its own and partner devices, solutions, and services, across the continuum of care in diabetes. Some prominent players in the global blood glucose monitoring devices market include:
Abbott Laboratories
Medtronic plc
F. Hoffmann-La Roche Ltd.
Ascensia Diabetes Care
Dexcom, Inc.
Sanofi
Novo Nordisk
Insulet Corporation
Ypsomed Holdings
Glysens Incorporated
Report Attribute |
Details |
Market size value in 2022 |
USD 12.53 billion |
Revenue forecast in 2030 |
USD 23.15 billion |
Growth rate |
CAGR of 8.0% from 2022 to 2030 |
Base year for estimation |
2021 |
Historical data |
2017 - 2020 |
Forecast period |
2022 - 2030 |
Quantitative units |
Revenue in USD million/billion and CAGR from 2022 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Product, end-use, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; U.K.; Germany; France; Italy; Spain; Poland; Russia; Ukraine; Belarus; Turkey; China; Japan; India; Australia; South Korea; Kazakhstan; Uzbekistan; Mexico; Brazil; Colombia; Argentina; South Africa; Saudi Arabia; UAE |
Key companies profiled |
Abbott Laboratories; Medtronic plc; F. Hoffmann-La Roche Ltd.; Ascensia Diabetes Care; Dexcom, Inc.; Sanofi; Novo Nordisk; Insulet Corporation; Ypsomed Holdings; GlySens Incorporated |
Customization scope |
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional, and segment scope |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2017 to 2030. For this study, Grand View Research has segmented the global blood glucose monitoring devices market report based on product, end-use, and region:
Product Outlook (Revenue, USD Million, 2017 - 2030)
Self-monitoring Devices
Blood Glucose Meter
Testing Strips
Lancets
Continuous Blood Glucose Monitoring Devices
Sensors
Transmitter & Receiver
Insulin Pumps
End-use Outlook (Revenue, USD Million, 2017 - 2030)
Hospitals
Home Care
Diagnostic Centers
Regional Outlook (Revenue, USD Million, 2017 - 2030)
North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Poland
Russia
Ukraine
Belarus
Turkey
Asia Pacific
Japan
China
India
Australia
South Korea
Kazakhstan
Uzbekistan
Latin America
Brazil
Mexico
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
b. The global blood glucose monitoring devices market size was estimated at USD 11.71 billion in 2021 and is expected to reach USD 12.53 billion in 2022.
b. The global blood glucose monitoring devices market is expected to grow at a compound annual growth rate of 8.0% from 2022 to 2030 to reach USD 23.1 billion by 2030.
b. North America dominated the blood glucose monitoring devices market with a share of 39% in 2021. This is attributable to the rising incidence of diabetes coupled with an increasing number of product launches.
b. Some key players operating in the blood glucose monitoring devices market include Abbott Laboratories, Medtronic plc, F. Hoffmann-La Roche Ltd, Ascensia Diabetes Care, Dexcom, Inc., Sanofi, Novo Nordisk, Insulet Corporation, Ypsomed Holdings, Glysens Incorporated
b. Key factors that are driving the blood glucose monitoring devices market growth include increasing healthcare expenditure related to diabetes and technological advancement.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
We value your investment and offer free customization with every report to fulfil your exact research needs.